StockData
LeMaitre Vascular Inc logo

LeMaitre Vascular Inc (LMAT) company profile

LMATNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 22/3022% below fair value
$76.10−0.91 (-1.18%)

Close on Nov 17, 2026Market cap $1.74BP/E 26.7Yield 1.05%

About LeMaitre Vascular

Surgical & Medical Instruments & Apparatus, SIC 3841

LeMaitre Vascular, Inc. is a medical device company that develops, manufactures, and markets vascular devices and provides human tissue cryopreservation services. Its products are primarily designed for use in open surgical procedures, including open vascular and open cardiac surgeries, to treat peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company's portfolio features six product categories encompassing twenty-four distinct product types, such as valvulotomes, balloon catheters, carotid shunts, vascular grafts, patches, and vessel closure systems. LeMaitre Vascular primarily serves vascular surgeons, while also providing products and tissue processing services to cardiac surgeons, general surgeons, and neurosurgeons.

The company operates globally, conducting direct-to-hospital sales and marketing through regional headquarters and offices across North America, Europe, and Asia Pacific. Its corporate headquarters is located in Burlington, Massachusetts, where it also maintains primary manufacturing operations. Additional corporate and sales presences include a European headquarters in Sulzbach, Germany, an Asia Pacific headquarters in Singapore, and multiple regional sales offices in countries such as Canada, Italy, Spain, England, Ireland, France, Switzerland, Japan, China, Australia, Korea, and Thailand. Outside these direct territories, the company distributes products via independent distributors.

Summary of the business section of LeMaitre Vascular's latest annual report, written by StockData.

Company profile

Company

Legal name
LeMaitre Vascular Inc
Founded
1983
Headquarters
Burlington, MA
Address
63 Second Avenue 01803
Phone
(781) 221-2266
Employees
655, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Boston, Massachusetts

Stock & identifiers

Ticker
LMAT
Exchange
Nasdaq
IPO date
Oct 19, 2006
Shares outstanding
23M, Aug 2, 2026
Public float
$1.70B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1158895
CUSIP
525558201
ISIN
US5255582018
FIGI
BBG000LY1HS2
Share class FIGI
BBG001SK6CX3
LEI
549300FZUBUB7MHY8R17
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
George W. LeMaitreChairman and CEO, Director1,463,419
David B. RobertsPresident and Director14,667
Dorian Paul LeBlancChief Financial Officer2,302
Trent G. KamkeSenior V. P., Operations3,749
John James O'ConnorDirector62,826
John A. RoushDirector7,567
Lawrence J. JasinskiDirector7,792
Martha ShadanDirector2,961
Joseph P. Pellegrino JRDirector15,021
Bridget A. RossDirector8,986

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.78B$4.21B$911.59M$210000$116000
FY2024$3.24B$8.32B$1.11B$236000$109000
FY2023$2.22B$4.43B$956.47M$144000$100000
FY2022$1.94B$2.43B$876.24M$116000$97000
FY2021$1.98B$5.34B$905.07M$125000$121000
FY2020$1.39M$3.11M$598.05K$114$124

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
George W. LeMaitre
Chairman and Chief Executive Officer
$806.35K–$1.05M$1.05M$680.02K$194.63K$3.78M+17%
Joseph P. Pellegrino, Jr.
Former Chief Financial Officer
$88.82K$2.83K–––$244.24K$335.89K-74%
Dorian P. LeBlanc
Chief Financial Officer
$445.48K$8.00K$196.88K$196.88K$220.06K$10.50K$1.08M–
David B. Roberts
President
$452.71K$40.50K$283.50K$283.50K$202.64K$10.50K$1.27M+11%
Trent G. Kamke
Senior Vice President, Operations
$383.82K$12.00K$196.88K$196.88K$159.25K$10.50K$859.35K0%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 19, 2006
Offer price
$7.00
Securities offered
5,500,000
Gross proceeds
$38.50M
Exchange
Nasdaq
First trading day
Oct 19, 2006
First-day close
$6.20-11.4%
Lock-up ends (est.)
Apr 17, 2007

“Per Share Total Initial public offering price $ 7.00 $ 38,500,000 Underwriting discount $ 0.49 $ 2,695,000 Proceeds, before expenses, to LeMaitre Vascular $ 6.51 $ 35,805,000 To the extent that the underwriters sell more than 5,500,000 shares of common stock, the underwriters have the option to purchase up to an ad”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We had 655 employees, including 646 full-time employees, as of December 31, 2025.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?